Company intelligence / Profile preview

Baszucki Group

San Mateo, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Baszucki Group funds and supports translational and mechanistic clinical trials evaluating ketogenic and other metabolic therapies for serious mental illnesses, with recent grants supporting pilot trials and multidisciplinary research on mitochondrial biology and gene expression in bipolar disorder. Early clinical results indicate potential for robust symptom improvement in bipolar disorder and other mental health conditions when using ketogenic diet interventions[1][10].

Therapeutic areas: Psychiatry
Modalities: Dietary interventionNutritional therapyMetabolic therapy
Industry: Investors

Partnerships

University of Pittsburgh Department of PsychiatryPhillips Mood and Brain LaboratoryUniversity of Toronto

Beyond the preview

Go deeper on Baszucki Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baszucki Group.

Explore the full profile